Analysed LANTERN PHARMA INC (LTRN:NASDAQ) News Sources
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
29-04-2026
yahoo.com
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™
07-05-2026
yahoo.com
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
11-05-2026
yahoo.com
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
13-05-2026
yahoo.com
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
14-05-2026
yahoo.com
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
15-05-2026
yahoo.com
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
19-05-2026
yahoo.com
What is the current price of LANTERN PHARMA INC (LTRN:NASDAQ)?
The current price of LANTERN PHARMA INC (LTRN:NASDAQ) is $3.59.
LANTERN PHARMA INC (LTRN:NASDAQ) absolute price change since previous trading day?
The absolute price change of LANTERN PHARMA INC (LTRN:NASDAQ) since the previous trading day is $0.09.
LANTERN PHARMA INC (LTRN:NASDAQ) percentage price change since previous trading day?
The percentage price change of LANTERN PHARMA INC (LTRN:NASDAQ) since the previous trading day is 2.5714%.
What is the most recent average sentiment score for LANTERN PHARMA INC (LTRN:NASDAQ)?
The most recent average sentiment score for LANTERN PHARMA INC (LTRN:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for LANTERN PHARMA INC (LTRN:NASDAQ)?
The most recent sentiment for LANTERN PHARMA INC (LTRN:NASDAQ) is .
SEC-8K** Filing Available For LANTERN PHARMA INC (LTRN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.